| |
|
|
|
| Data collected prospectively from patients hospitalized with unstable angina or non–Q-wave MI. *Organization to Assess Strategies for Ischemic Syndromes. ... |
|
|
|
|
| Hyperlipidemia is an important risk factor, and should be used to assess overall cardio-vascular risk; Global CV risk should be used to assess treatment ... |
|
|
|
|
| LDL-cholesterol levels similar to non-diabetics, but with higher proportion of smaller & denser LDL particles. Diabetic Dyslipidemia ADA GUIDELINES … |
|
|
|
|
| Many High-Risk Patients Are Not Reaching NCEP LDL-C GoalsThe NCEP recommends lowering LDL-C even further than these goals if possible … |
|
|
|
|
| LDL-cholesterol levels similar to non-diabetics, but with higherLargest number ( 5963 ) of patients with diabetes & cholesterol of > 135 mg/dL. ... |
|
|
|
|
| Since hyperlipidemia is important as a risk factor, it should be used to assess overall cardiac risk,Physical signs of hyperlipidemia (at any age): ... |
|
|
|
|
| Statin therapy in Canadian patients with hypercholesterolemia: the CALIPSO study.goals, Canadian Working Group on Hypercholesterolemia and ... |
|
|
|
|
| Glucose intolerance . Macrovascular disease . Endothelial dysfunction . Dysfibrinolysis . Dyslipidemia . Obesity . Hyperglycemia . Insulin . resistance |
|
|
|
|
| Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)Despres J-P, Golay A, Sjostrom L, the Rimonabant in Obesity-Lipids Study Group. … |
|
|
|
|
| Marketed as a “risk reduction” or “preventive cardiology” clinic; May focus on management of a particular disorder such as dyslipidemia or hypertension, ... |
|
|
